We saw a significant improvement in the Zubsolv market share in February (4w rolling average), which rose to 5.7% (measured in quantity) and to 5.2% (measured in prescriptions). The underlying buprenorphine/naloxone market grew y/y by 9.5% (measured in quantity) and by 9.3% (measured in prescriptions).